Vtv Therapeutics Stock Price, News & Analysis

vTv Therapeutics Inc. (Nasdaq:VTVT) reported its Q3 2020 financial results, revealing a net loss of $2.3 million, an improvement from $5.0 million in Q2. Cash reserves dropped to $1.8 million from $6.4 million. The company concluded enrollment in the Elevage Study of azeliragon for Alzheimer's, expecting topline results in December 2020. Plans for further studies of TTP399 are underway, including a mechanistic study and pivotal trials for type 1 diabetes. R&D expenses decreased to $1.8 million, while G&A expenses were $1.1 million, both showing cost management efforts.

vTv Therapeutics Inc. (Nasdaq: VTVT) announced baseline characteristics from the Elevage clinical study, which evaluates azeliragon for mild Alzheimer's disease in patients with type 2 diabetes. The study includes 43 enrolled patients, showing similar characteristics to a previous subgroup from the STEADFAST trial. Preliminary data suggest the potential efficacy of azeliragon, with the company expecting to report topline results in December 2020. The Elevage study aims to confirm prior findings in a 6-month Phase 2 trial before moving to Phase 3.

vTv Therapeutics Inc. (Nasdaq: VTVT) will present at the 13th Clinical Trials on Alzheimer’s Disease Digital Event on November 4, 2020. The presentation will showcase data from the phase 2 Elevage Study of azeliragon, aimed at treating mild-probable Alzheimer’s in patients with type 2 diabetes. Patient enrollment was completed in September 2020, with topline results expected in December 2020. Preliminary analysis reveals statistically significant cognitive improvements in a subgroup of patients treated with azeliragon compared to placebo, suggesting potential efficacy of the treatment.

vTv Therapeutics (Nasdaq: VTVT) announced positive results from the Phase 2 Simplici-T1 study for TTP399, an oral adjunctive therapy for type 1 diabetes (T1D). Data indicated that TTP399 does not raise the risk of diabetic ketoacidosis (DKA) and leads to significant reductions in HbA1c without increasing hypoglycemia risk. These findings support further development of TTP399, with plans for a pivotal study expected by end of 2020. The study was presented at the European Association for the Study of Diabetes Annual Meeting.

vTv Therapeutics has appointed Edward P. Taibi, Executive Vice President at MacAndrews & Forbes, to its Board of Directors, effective August 31, 2020. This strategic move aims to enhance the company's leadership as it pursues its clinical drug development pipeline targeting type 1 diabetes and Alzheimer’s disease. Mr. Taibi brings extensive experience in business leadership and capital markets from his previous roles. MacAndrews has a significant investment history in vTv, impacting its business strategies.

vTv Therapeutics Inc. (Nasdaq: VTVT) reported its second-quarter 2020 financial results, showing significant progress in advancing its TTP399 drug for type 1 diabetes, with upcoming pivotal studies planned by year-end. The firm is also actively enrolling patients for its Alzheimer's treatment study, despite COVID-19 challenges.

Financially, cash reserves increased to $6.4 million, while R&D expenses decreased to $2.5 million. The net loss for the quarter was $5.0 million, an improvement from the previous quarter's $7.2 million loss. Revenue remained negligible, reflecting ongoing developmental focus.

vTv Therapeutics (Nasdaq: VTVT) announced its participation in the 2020 Alzheimer's Association International Conference (AAIC) from July 27-31, 2020. The company will present a poster showcasing analyses from the STEADFAST Study of azeliragon, which examines its effects on cognitive functions in Alzheimer's patients with type 2 diabetes. The presentation is scheduled for July 29, 2020, at 5:00 pm CT. The STEADFAST study consists of two Phase 3 trials investigating azeliragon's safety and efficacy as a treatment for mild Alzheimer's disease.

vTv Therapeutics (Nasdaq: VTVT) presented positive data from the Phase 2 Simplici-T1 Study at the American Diabetes Association’s 80th Scientific Sessions. The trial demonstrated that TTP399, a once-daily oral treatment, significantly reduced HbA1c levels by 0.3% compared to placebo (p<0.01), without increasing the risk of hypoglycemia or diabetic ketoacidosis. The study involved 85 subjects, confirming promising results from prior phases. TTP399 may provide a valuable adjunctive therapy for type 1 diabetes patients, aiming to enhance glucose control while minimizing insulin requirements.

vTv Therapeutics (Nasdaq: VTVT) has announced that two late-breaking abstracts showcasing TTP399 as an oral adjunctive therapy for type 1 diabetes will be virtually presented at the American Diabetes Association’s 80th Scientific Sessions from June 12–16, 2020. The Phase 2 (Part 2) Simplici-T1 trial showed TTP399's positive impact on lowering HbA1c, reducing insulin dosage, and increasing Time in Range in T1D patients. The trial's presentations on June 13 will provide further data supporting these findings.